Anzeige
Meldung des Tages: UBS spricht von der dritten großen Lithium-Preisphase - und EMP setzt bereits operativ um
07.02.26
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-​breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-​inferiority compared to the current standard of ...
06.02.26
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end ‑ to ‑ end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and ...
06.02.26
Smartkem Announces Significant Reduction in Accounts Payable Through Debt Conversion Agreement
MANCHESTER, United Kingdom, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Smartkem, Inc. ( Nasdaq: SMTK ), (“Smartkem” or the “Company”), a leader in advanced materials, today ...
06.02.26
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~
06.02.26
Norsk Hydro: Reminder - Invitation to Hydro's fourth quarter results 2025
Hydro's fourth quarter results 2025 will be released at 07:00 CET (01:00 EDT, 06:00 UTC/GMT) on February 13, 2025. The integrated annual report 2025 will be released the same ...
06.02.26
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
Allschwil, Switzerland – February 06, 2026 Idorsia Ltd (SIX: IDIA) announces the design of its FDA-​agreed Phase 3 registration program for lucerastat in Fabry disease. Building on ...
06.02.26
Telenor reports strong results and announces NOK 15 billion share buyback programme
Telenor enters 2026 with strong Nordic growth, a solid financial position, and a simplified portfolio in line with the ambitions presented at the Capital Markets Day.
05.02.26
WillScot to Announce Fourth Quarter and Full Year 2025 Results on February 19, 2026
SCOTTSDALE, Ariz., Feb. 05, 2026 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space ...
05.02.26
Fortinet Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Fourth Quarter 2025 Highlights
05.02.26
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
Bagsværd, Denmark and Plainsboro, NJ, 5 February 2026 – Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully ...
05.02.26
Ingredion Incorporated gibt Ergebnisse für das vierte Quartal und das Gesamtjahr 2025 bekannt
Der ausgewiesene und bereinigte * Gewinn pro Aktie belief sich für das Gesamtjahr 2025 auf 11,18 USD bzw. 11,13 USD, verglichen mit 9,71 USD bzw. 10,65 USD für das ...
05.02.26
ZenaTech’s Drone as a Service Announces Initiation of its Golf Course Survey Services Across Florida
VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology solution provider ...
05.02.26
Shell plc publishes fourth quarter 2025 press release
London, February 5, 2026
04.02.26
Clariant acknowledges the agreement between Wendel SE and Henkel on the acquisition of Stahl
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
04.02.26
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange ...
04.02.26
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 ...
04.02.26
Plug Power Completes First Hydrogen Fill for Hynetwork’s Important Segment in Rotterdam with Delivery of 32 Tons of RFNBO Hydrogen and Custom Infrastructure
Commissioning marks a major step in building Europe’s hydrogen backbone, positioning Plug as a key end-​to-end solutions provider supporting the scale-up of clean hydrogen ...
04.02.26
Betfred Deepens Technology Partnership With Sportradar to Ensure a Long-Term and Sustainable Retail Betting Offering
ST GALLEN, Switzerland, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Betfred has extended and expanded its longstanding agreement with Sportradar (NASDAQ: SRAD). As part of the ...
04.02.26
Publicis Advances Working With Cancer with initiative to support 40 million workers worldwide
Publicis Advances Working With Cancer  with initiative to support 40 million workers worldwide.  New research reinforces the link between work and recovery, inspiring WWC’s AI ...
04.02.26
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury
Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM ® System to address blood pressure instability after spinal cord ...